In a space that's given many drug developers grief, Plexxikon Inc. had reason to be overjoyed this week, reporting a stunning 81 percent of metastatic melanoma patients with the BRAF V600E mutation had tumor shrinkage of at least 30 percent after receiving twice-daily dosages of PLX4032 (RG7204), a highly selective kinase inhibitor. (BioWorld Today) Read More
